NCT06641557View on ClinicalTrials.gov

A Phase I Dosing Study of IkT-148009.

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 21, 2023

Primary Completion Date

March 21, 2023

Study Completion Date

April 19, 2023

Conditions
Healthy
Interventions
DRUG

200mg of Ikt-148009

4 50mg capsules

Trial Locations (1)

68502

Celerion, Lincoln

Sponsors
All Listed Sponsors
lead

ABLi Therapeutics, Inc.

INDUSTRY